Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823743 | 0.95 | CYP2D6 (0.49) | CYP2D6CYP2C19ADRA1AGRM5L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL18185643 | 0.93 | ADRA1A (0.47) | ADRA1AGRM5L3MBTL1L3MBTL3 | |
| Trifluoroacetic Acid SCHEMBL18185604 | 0.91 | GRM5 (0.51) | ADRA1AGRM5L3MBTL1L3MBTL3 | |
| Trifluoroacetic Acid SCHEMBL18185565 | 0.91 | ADRA1A (0.49) | ADRA1AL3MBTL1KDM4EL3MBTL3MEN1 | |
| Trifluoroacetic Acid SCHEMBL18185583 | 0.90 | ADRA1A (0.46) | ADRA1AGRM5L3MBTL1L3MBTL3KMT2A | |
| Trifluoroacetic Acid SCHEMBL18185616 | 0.87 | ADRA1A (0.49) | ADRA1AL3MBTL1L3MBTL3TDP1 | |
| SCHEMBL16845177 | 0.87 | ADRA1A (0.51) | ADRA1AGRM5L3MBTL1L3MBTL3 | |
| SCHEMBL16845176 | 0.86 | ADRA1A (0.53) | ADRA1AL3MBTL1KDM4EL3MBTL3MEN1 | |
| SCHEMBL16823817 | 0.85 | GRM5 (0.56) | ADRA1AGRM5L3MBTL1L3MBTL3 | |
| Trifluoroacetic Acid SCHEMBL18185566 | 0.85 | ADRA1A (0.46) | ADRA1AGRM5L3MBTL1KDM4EL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNI3, TNNC1, FABP3 | CYP2D6 1797/4885CYP2C19 3004/4885ADRA1A 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.